Skip to main content

Table 2 Values, notes, and sources for variables used to predict HCV infection reduction savings

From: Mitigating the heroin crisis in Baltimore, MD, USA: a cost-benefit analysis of a hypothetical supervised injection facility

Variable Value Note Source
Proportion of PWID HCV− (I) 25% Average of values reported (10–40%) Falade-Nwulia et al. [89]
Number of needles in circulation (N) 1,600,000 Increased by 33% due to additional syringe sources Hunt and Parker [81]; German et al. [4]
Rate of needle sharing (s) 2.8% Percent of injections with a shared needle Park et al. [83]
Percentage of needles not bleached (d) 100%   Bluthenthal et al. [84]
Proportion of PWID HCV+ (q) 75% Average of values reported (60–90%) Falade-Nwulia et al. [89]
Probability of HCV infections from a single injection (t) 3%   Kwon et al. [86]; Kaplan and O’Keefe [85]
Number of sharing partners (m) 1.2 Per injection: ratio of receptive to distributive sharing Park et al. [83]
SIF client reduction in needle-sharing (n) 70% From Insite Kerr et al. [40]
Number of SIF clients (N) 2100 Approximate monthly unique Insite injection room clients Maynard [33]
Total PWID population (T) 20,950 Adjusted by authors from Baltimore MSA to City using race census data Tempalski et al. [87]
Lifetime HCV treatment cost $68,219 Adjusted for inflation Razavi et al. [90]